← SGLT2 inhibitors × cardiovascular events

TrialNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2022

Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.

Rajiv Agarwal et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 2022

Randomised comparison

Probably reduced cardiovascular events

−30%−41% to −18%

Bigger than 7 in 10 for cardiovascular events

As reported

HR 0.70, 95% CI 0.59–0.82

One number in the abstract

the abstract, start to end

… was observed with canagliflozin [HR 0.70 (95% CI 0.59-0.82)].

← favours treatmentfavours comparator →
could be chance
Cardiovascular events
HR 0.700.59–0.82
SGLT2 inhibitorsCardiovascular events

SGLT2 inhibitors × cardiovascular eventshelps?mixed

unlikelylikely
0.500.50 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

23 papers cite it

2022
2023
2024
2025
2026
this paperpooled itcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 34850173